These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 36868123)
1. Neutrophil-to-Lymphocyte Ratio Is Associated With the Proportion of Poorly Differentiated Components in Papillary Thyroid Carcinoma. Oba T; Maeno K; Kiyosawa N; Morikawa H; Amitani M; Chino T; Shimizu T; Ono M; Ito T; Kanai T; Uehara T; Ito KI J Surg Res; 2023 Jul; 287():47-54. PubMed ID: 36868123 [TBL] [Abstract][Full Text] [Related]
2. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma? Lang BH; Ng CP; Au KB; Wong KP; Wong KK; Wan KY World J Surg; 2014 Oct; 38(10):2605-12. PubMed ID: 24809487 [TBL] [Abstract][Full Text] [Related]
3. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders? Kocer D; Karakukcu C; Karaman H; Gokay F; Bayram F Asian Pac J Cancer Prev; 2015; 16(9):3875-9. PubMed ID: 25987053 [TBL] [Abstract][Full Text] [Related]
4. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568 [No Abstract] [Full Text] [Related]
5. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer. Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074 [TBL] [Abstract][Full Text] [Related]
6. The Neutrophil-to-Lymphocyte Ratio Correlates with Age in Patients with Papillary Thyroid Carcinoma. Liu J; Du J; Fan J; Liu K; Zhang B; Wang S; Wang W; Wang Z; Cai Y; Li C; Yu T; Zhu G; Chen J; Li C ORL J Otorhinolaryngol Relat Spec; 2015; 77(2):109-16. PubMed ID: 25896501 [TBL] [Abstract][Full Text] [Related]
7. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the correlation of neutrophil/lymphocyte ratio with prognostic classification systems in papillary thyroid carcinoma patients. Yildiz EO; Işcen K; Kaya F; Güney OA; Ulukent SC Medicine (Baltimore); 2024 Feb; 103(5):e37210. PubMed ID: 38306518 [TBL] [Abstract][Full Text] [Related]
9. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer. Cho JS; Park MH; Ryu YJ; Yoon JH Ann Surg Treat Res; 2015 Apr; 88(4):187-92. PubMed ID: 25844352 [TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas. Kim JY; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC; Ha WS; Choi SK; Jung EJ Endocrine; 2014 Aug; 46(3):526-31. PubMed ID: 24272600 [TBL] [Abstract][Full Text] [Related]
11. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior. Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Ozmen S; Timur O; Calik I; Altinkaynak K; Simsek E; Gozcu H; Arslan A; Carlioglu A Endocr Regul; 2017 Jul; 51(3):131-136. PubMed ID: 28858848 [TBL] [Abstract][Full Text] [Related]
13. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report. Thewjitcharoen Y; Krittiyawong S; Butadej S; Nakasatien S; Polchart S; Junyangdikul P; Kanchanapituk A; Himathongkam T Medicine (Baltimore); 2020 Apr; 99(16):e19892. PubMed ID: 32312017 [TBL] [Abstract][Full Text] [Related]
14. Significance of multifocality in papillary thyroid carcinoma. Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090 [TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. Sugitani I; Toda K; Yamamoto N; Sakamoto A; Fujimoto Y World J Surg; 2010 Jun; 34(6):1265-73. PubMed ID: 19953247 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963 [TBL] [Abstract][Full Text] [Related]
17. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
18. Relationship Between Serum Inflammatory Factor Levels and Differentiated Thyroid Carcinoma. Zhang X; Li S; Wang J; Liu F; Zhao Y Technol Cancer Res Treat; 2021; 20():1533033821990055. PubMed ID: 33752541 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country. Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292 [TBL] [Abstract][Full Text] [Related]